Nature Reviews Cancer最新文献

{"title":"Thelpers? More like Ttroublemakers","authors":"Gabrielle Brewer","doi":"10.1038/s41568-024-00741-3","DOIUrl":"10.1038/s41568-024-00741-3","url":null,"abstract":"Inflammation is well established as a risk factor for cancer development in the gut. In this study, Fesneau et al. identify a specific immune cell population, derived from T helper 17 (TH17) cells, that can initiate intestinal cancer.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 10","pages":"651-651"},"PeriodicalIF":72.5,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142002771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative medicine in oncology: redefining the standard of care","authors":"Gabriel Lopez, Santhosshi Narayanan, Lorenzo Cohen","doi":"10.1038/s41568-024-00735-1","DOIUrl":"10.1038/s41568-024-00735-1","url":null,"abstract":"Integrative medicine incorporated alongside cancer care, referred to as integrative oncology, is an evidence-informed field with established clinical guidelines. Although integrative oncology improves patient outcomes, it is inconsistently provided to patients. To align with best practices, it is necessary to increase awareness of integrative oncology, improve access to treatments, and provide consistent financial healthcare coverage.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 11","pages":"739-740"},"PeriodicalIF":72.5,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141991999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tracing the evolutionary history of breast cancer","authors":"Jiwon Koh, Seock-Ah Im","doi":"10.1038/s41568-024-00733-3","DOIUrl":"10.1038/s41568-024-00733-3","url":null,"abstract":"In this Journal Club, Koh and Im discuss a study demonstrating the unique evolutionary trajectory of breast cancers harbouring the common driver alteration der(1;16).","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 10","pages":"653-653"},"PeriodicalIF":72.5,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141982804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tertiary lymphoid structures in anticancer immunity","authors":"Jean-Luc Teillaud, Ana Houel, Marylou Panouillot, Clémence Riffard, Marie-Caroline Dieu-Nosjean","doi":"10.1038/s41568-024-00728-0","DOIUrl":"10.1038/s41568-024-00728-0","url":null,"abstract":"Tertiary lymphoid structures (TLS) are transient ectopic lymphoid aggregates where adaptive antitumour cellular and humoral responses can be elaborated. Initially described in non-small cell lung cancer as functional immune lymphoid structures associated with better clinical outcome, TLS have also been found in many other carcinomas, as well as melanomas and sarcomas, and associated with improved response to immunotherapy. The manipulation of TLS as a therapeutic strategy is now coming of age owing to the likely role of TLS in the improved survival of patients with cancer receiving immune checkpoint inhibitor treatment. TLS have also garnered considerable interest as a predictive biomarker of the response to antitumour therapies, including immune checkpoint blockade and, possibly, chemotherapy. However, several important questions still remain regarding the definition of TLS in terms of both their cellular composition and functions. Here, we summarize the current views on the composition of TLS at different stages of their development. We also discuss the role of B cells and T cells associated with TLS and their dialogue in mounting antibody and cellular antitumour responses, as well as some of the various mechanisms that negatively regulate antitumour activity of TLS. The prognostic value of TLS to the clinical outcome of patients with cancer and the relationship between TLS and the response to therapy are then addressed. Finally, we present some preclinical evidence that favours the idea that manipulating the formation and function of TLS could lead to a potent next-generation cancer immunotherapy. Transient ectopic lymphoid structures known as tertiary lymphoid structures (TLS) have been observed in many solid tumour types. In this Review, Teillaud et al. discuss how these TLS potentially orchestrate immune responses against tumours locally and are positively associated with prognosis and response to immune checkpoint inhibitors. The authors also outline how preclinical studies are highlighting the potential to manipulate the formation and function of TLS as a novel form of immunotherapy.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 9","pages":"629-646"},"PeriodicalIF":72.5,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141907156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lactate promotes DNA repair","authors":"Daniela Senft","doi":"10.1038/s41568-024-00732-4","DOIUrl":"10.1038/s41568-024-00732-4","url":null,"abstract":"In a recent study published in Nature, lactate has been identified as a key player in enhancing DNA repair mechanisms in gastric cancer by promoting lactylation of DNA repair proteins, leading to chemotherapy resistance.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 9","pages":"593-593"},"PeriodicalIF":72.5,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141891691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Publisher Correction: Structural variations in cancer and the 3D genome","authors":"Frank Dubois, Nikos Sidiropoulos, Joachim Weischenfeldt, Rameen Beroukhim","doi":"10.1038/s41568-024-00738-y","DOIUrl":"10.1038/s41568-024-00738-y","url":null,"abstract":"","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 10","pages":"735-735"},"PeriodicalIF":72.5,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41568-024-00738-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shared immunosuppressive mechanism between pregnancy and cancer","authors":"Linda Gummlich","doi":"10.1038/s41568-024-00731-5","DOIUrl":"10.1038/s41568-024-00731-5","url":null,"abstract":"Pregnancy involves immune system suppression to protect the fetus, making it a valuable model for understanding cancer immune tolerance. Recently in Cell, Yu et al. identified B7-H4 as a common immune tolerance checkpoint in both tumours and the placenta.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 9","pages":"595-595"},"PeriodicalIF":72.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141875413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rational combination of cancer therapies with PD1 axis blockade","authors":"","doi":"10.1038/s41568-024-00727-1","DOIUrl":"https://doi.org/10.1038/s41568-024-00727-1","url":null,"abstract":"This poster explores rational combinations of immune checkpoint blockade of the PD1–PDL1 interaction with other therapies aimed at targeting effector T cells, innate immune and regulatory cells, the tumour microenvironment and cancer cells.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"6 1","pages":""},"PeriodicalIF":78.5,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141794583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circular RNA in cancer","authors":"Vanessa M. Conn, Arul M. Chinnaiyan, Simon J. Conn","doi":"10.1038/s41568-024-00721-7","DOIUrl":"10.1038/s41568-024-00721-7","url":null,"abstract":"Over the past decade, circular RNA (circRNA) research has evolved into a bona fide research field shedding light on the functional consequence of this unique family of RNA molecules in cancer. Although the method of formation and the abundance of circRNAs can differ from their cognate linear mRNA, the spectrum of interacting partners and their resultant cellular functions in oncogenesis are analogous. However, with 10 times more diversity in circRNA variants compared with linear RNA variants, combined with their hyperstability in the cell, circRNAs are equipped to influence every stage of oncogenesis. This is an opportune time to address the breadth of circRNA in cancer focused on their spatiotemporal expression, mutations in biogenesis factors and contemporary functions through each stage of cancer. In this Review, we highlight examples of functional circRNAs in specific cancers, which satisfy critical criteria, including their physical co-association with the target and circRNA abundance at stoichiometrically valid quantities. These considerations are essential to develop strategies for the therapeutic exploitation of circRNAs as biomarkers and targeted anticancer agents. Circular RNAs, once considered by-products of splicing errors, are now accepted as key players in cancer biology. In this Review, Conn et al. review the functional interactome of circular RNAs in cancer, highlighting their contribution to oncogenesis, their potential as biomarkers and the prospect of leveraging them for novel therapeutics.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 9","pages":"597-613"},"PeriodicalIF":72.5,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141790950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance","authors":"Nils Wellhausen, Joanne Baek, Saar I. Gill, Carl H. June","doi":"10.1038/s41568-024-00723-5","DOIUrl":"10.1038/s41568-024-00723-5","url":null,"abstract":"Adoptive cell therapies engineered to express chimeric antigen receptors (CARs) or transgenic T cell receptors (TCRs) to recognize and eliminate cancer cells have emerged as a promising approach for achieving long-term remissions in patients with cancer. To be effective, the engineered cells must persist at therapeutically relevant levels while avoiding off-tumour toxicities, which has been challenging to realize outside of B cell and plasma cell malignancies. This Review discusses concepts to enhance the efficacy, safety and accessibility of cellular immunotherapies by endowing cells with selective resistance to small-molecule drugs or antibody-based therapies to facilitate combination therapies with substances that would otherwise interfere with the functionality of the effector cells. We further explore the utility of engineering healthy haematopoietic stem cells to confer resistance to antigen-directed immunotherapies and small-molecule targeted therapies to expand the therapeutic index of said targeted anticancer agents as well as to facilitate in vivo selection of gene-edited haematopoietic stem cells for non-malignant applications. Lastly, we discuss approaches to evade immune rejection, which may be required in the setting of allogeneic cell therapies. Increasing confidence in the tools and outcomes of genetically modified cell therapy now paves the way for rational combinations that will open new therapeutic horizons. Adoptive cell therapies have emerged as promising approaches for the treatment of patients with cancer. Engineering cell therapies to confer resistance to small-molecule therapies, chemotherapies and antibody-based therapies will improve their utility and success. Here, Wellhausen, Baek and colleagues outline the key principles of engineering resistance and potential applications for haematopoietic stem cell transplantation and allogeneic immune cell therapies.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"24 9","pages":"614-628"},"PeriodicalIF":72.5,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141754705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}